| | Class 2 Device Recall QuickTox |  |
| Date Initiated by Firm | August 18, 2020 |
| Create Date | September 30, 2020 |
| Recall Status1 |
Terminated 3 on September 30, 2024 |
| Recall Number | Z-3043-2020 |
| Recall Event ID |
86335 |
| Product Classification |
Enzyme immunoassay, cocaine and cocaine metabolites - Product Code DIO
|
| Product | QuickTox Drug Screen DipCard(AMT Item/ AMT Description):
QT70/ "QuickTox Drug Screen Dipcard 11 Drug Detection: COC300+OPI300+MET500+THC50+AMP1000+PCP25+BZO300+BAR300+MTD300+OXY100+MDMA500",
QT88/ "QuickTox Drug Screen Dipcard 12 Drug Detection: COC300+OPI300+MET500+THC50+AMP1000+PCP25+BZO300+BAR300+MTD300+OXY100+ MDMA500+BUP10",
QT11 / "QuickTox Drug Screen Dipcard
5 Drug Detection: COC300+OPI2000+THC50+AMP1000+PCP25",
QT52/ "QuickTox Drug Screen Dipcard 9 Drug Detection: COC300+OPI300+MET500+THC50+AMP1000+BZO300+BAR300+MTD300+OXY100",
QT44/ "QuickTox Drug Screen Dipcard 8 Drug Detection: COC300+OPI300+MET500+THC50+AMP1000+BZO300+BAR300+OXY100",
QT23/ "QuickTox Drug Screen Dipcard 6 Drug Detection: COC300+OPI2000+MET500+THC50+AMP1000+PCP25",
QT80F/ "QuickTox Drug Screen Dipcard 12 Drug Detection: COC300+OPI300+MET500+THC50+AMP1000+PCP25+BZO300+BAR300+MTD300+TCA1000+OXY100+MDMA500 with Positive Control Line",
QT52A/ "QuickTox Drug Screen Dipcard 9 Drug Detection: COC300+OPI300+MET500+THC50+AMP1000+BZO300+BAR300+MTD300+OXY100 4 Adulteration Test: Cr, Ni, pH, Ox ",
QT20/ "QuickTox" Drug Screen Dipcard 5 Drug Detection: COC300+OPI2000+MET500+THC50+AMP1000" |
| Code Information |
ALL Lots Within Expiry |
| FEI Number |
3003789989
|
Recalling Firm/ Manufacturer |
Ameditech Inc 9940 Mesa Rim Rd San Diego CA 92121-2910
|
| For Additional Information Contact | Ms. Angela Occhionero 858-619-4969 |
Manufacturer Reason for Recall | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
FDA Determined Cause 2 | Process control |
| Action | A Field Corrective Action Notice letter was sent to affected consignees. The Customer notifications commenced on 19-Aug-2020. The consignees are requested to return all non-expired product in their possession to the recalling firm.
Method of Notification, 1st contact: Written field corrective action notification letters will be sent via certified mail with delivery tracking to each consignee along with a pre-paid return label to return any product remaining in stock. 2nd & 3rd contact: Telephone, follow up email, or written mail communication will be used as necessary. |
| Quantity in Commerce | 170,425 units |
| Distribution | US - Nationwide
OUS - Australia, France, Germany, New Zealand, Singapore and Spain |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
|
|
|